Warfarin News and Research

RSS

Warfarin is a drug that prevents blood from clotting. It belongs to the family of drugs called anticoagulants (blood thinners).

Herbal supplements aren't always safe!

Natural doesn’t always mean safe when it comes to herbal supplements, according to the August issue of Mayo Clinic Health Letter.

13 Aug 2009

Aryx Therapeutics reports Q2 2009 financials

ARYx Therapeutics, Inc. (NASDAQ:ARYX) today reported results of operations and provided a general business update for the second quarter ended June 30, 2009.

13 Aug 2009

Discovery of entirely new mechanism that promotes blood clot formation

A Monash-led research team has discovered an entirely new mechanism that promotes blood clot formation - a major breakthrough that will impact on treatment and prevention of heart disease and stroke.

26 May 2009

More patients needed in clinical trials to find treatment for patent foramen ovale (PFO)

The American Heart Association and the American College of Cardiology are calling on doctors to enroll more patients in clinical trials for catheter-based closure of patent foramen ovale (PFO), a condition caused when an opening between the two chambers of the heart fails to close at birth.

12 May 2009

Medicare will not pay for genetic tests to determine best Warfarin dosage, according to proposed decision

CMS will not provide Medicare coverage for a genetic test that physicians can use to determine the proper dosage of the blood thinner drug warfarin, the New York Times reports.

5 May 2009

Voice response system useful for monitoring anticoagulant patients

Interactive voice response systems may help improve monitoring of patients taking anticoagulants such as warfarin while reducing the workload of clinical staff, found a study by Ottawa researchers in CMAJ.

27 Apr 2009

FDA approves Symbyax for treatment-resistant depression

The U.S. Food and Drug Administration (FDA) has approved a new indication for Symbyax (olanzapine and fluoxetine HCl capsules), Eli Lilly and Company has announced.

23 Mar 2009

3 genes determine right warfarin dose

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin.

22 Mar 2009

Gleevec reduces risk of cancer returning in patients with life-threatening gastrointestinal stromal tumors

Data published online and in an upcoming print issue of The Lancet show that Gleevec (imatinib mesylate) tablets, when taken after surgery, substantially reduces the rate of recurrence of Kit-positive gastrointestinal stromal tumors (GIST) compared with placebo.

20 Mar 2009

Blood clots after hip and knee replacements

As the number of hip and knee replacements skyrocket into the coming years, patients and orthopaedic surgeons need to work together to evaluate and assess a potentially fatal complication - blood clots.

26 Feb 2009

Kidney disease affects response to anticoagulant drug warfarin

Patients with reduced kidney function require lower doses of the anticoagulant drug warfarin, and may need closer monitoring to avoid serious bleeding complications, suggests a study in the April 2009 issue of the Journal of the American Society of Nephrology ( JASN ).

20 Feb 2009

Optimizing dosage of blood-thinning drug warfarin

In a large-scale study and an upcoming clinical trial, scientists supported by the National Institutes of Health address one of the trickiest issues in prescribing medicine - how to quickly optimize each patient's dosage of the common blood-thinning drug warfarin.

20 Feb 2009

Genetic testing not cost-effective in guiding initial dosing of blood-thinner warfarin

New analyses led by the University of Cincinnati (UC) show that genetic testing used to guide initial dosing of the blood-thinner warfarin may not be cost-effective for typical patients with atrial fibrillation but may be for patients at higher risk for major bleeding.

19 Jan 2009

Savella - Fibromyalgia treatment approved by FDA

Forest Laboratories, Inc. and Cypress Bioscience, Inc. have announced that Savella (milnacipran HCl), a selective serotonin and norepinephrine dual reuptake inhibitor, was approved by the U.S. Food and Drug Administration (FDA) for the management of fibromyalgia.

19 Jan 2009

Seniors warned about mixing OTC and prescription drugs

According to researchers in the United States about 2.2 million seniors put themselves at high risk for drug interactions - they say many non-prescription medication, which are bought over-the-counter (OTC) can produce a harmful drug interactions.

29 Dec 2008

New approaches to prevent blood clots

The largest study ever to examine the preventive use of blood-thinning medication to help prevent deadly blood clots in patients with cancer undergoing chemotherapy presented December 7 during the 50th Annual Meeting of the American Society of Hematology in San Francisco, CA.

8 Dec 2008

Daiichi Sankyo starts trial of investigational factor Xa inhibitor for atrial fibrillation

Daiichi Sankyo Company, Limited, has announced that it has initiated its pivotal Phase III trial for DU-176b, an investigational oral Factor Xa inhibitor, in patients with atrial fibrillation. DU-176b is being developed solely by Daiichi Sankyo.

7 Dec 2008

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

3 Dec 2008

Liver disease tackled with dedicated unit at Imperial College London

Liver disease death rates are rising in the UK, in contrast to other common diseases such as heart disease and cancer, and the new Robert Hesketh Hepatology Clinical Research Facility aims to provide care and develop new therapies to reverse this trend.

1 Dec 2008

New plan to tackle off-label prescribing

Physicians and policy-makers know that drugs are frequently prescribed to treat certain diseases despite a lack of FDA approval - a practice known as off-label prescribing.

24 Nov 2008